On Tuesday 05/27/2025 the closing price of the Adaptive Biotechnologies Corporation Registered Shs share was $9.13 on BTT.
Compared to the opening price on Tuesday 05/27/2025 on BTT of $9.03, this is a gain of 1.10%.
Adaptive Biotechnologies Corporation Registered Shs's market capitalization is $1.16 B by 151.92 M shares outstanding.
Adaptive Biotechnologies Stock Snapshot
7.92
Bid
100.00
Bid Size
10.40
Ask
100.00
Ask Size
5/28/2025
Date
3:59 PM
Time
56,284.00
Volume
9.13
Prev. Close
9.03
Open
1.39 B
Market Cap in USD
151.92 M
Number of Shares
151.92 M
Total Number of Shares
8.99
Day Low
9.25
Day High
9.14
3.00
52 Week Low
10.27
52 Week High
9.14
0.00
Dividend in USD
0.00
Dividend Yield
95.39
Free Float in %
-1.08
EPS in USD
1.37
Book Value per Share in USD
-0.65
Cash Flow per Share in USD
Adaptive Biotechnologies Corporation Registered Shs News More News
Historical Prices for Adaptive Biotechnologies Corporation Registered Shs
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Adaptive Biotechnologies Corporation Registered Shs Analyst Data
Total Analysts: 14
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 5.00
Median: 9.54
Highest: 14.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Adaptive Biotechnologies Corporation Registered Shs Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/06/25 | Piper Sandler | Maintained Buy | $13 | |||
| 05/05/25 | Morgan Stanley | Maintained Hold | $9 | |||
| 05/02/25 | Goldman Sachs | Maintained Buy | $10 | |||
| 03/21/25 | Goldman Sachs | Upgraded to Buy | $9 | |||
| 02/20/25 | Piper Sandler | Maintained Buy | $11 | |||
| 01/28/25 | Goldman Sachs | Maintained Hold | $7.5 | |||
| 04/04/24 | BTIG Research | Maintained Buy | $5 | |||
| 02/16/24 | Goldman Sachs | Maintained Hold | $5 | |||
| 02/15/24 | J.P. Morgan | Maintained Buy | $8 | |||
| 11/13/23 | Piper Sandler | Maintained Buy | $6 | |||
| 10/24/23 | Morgan Stanley | Maintained Hold | $10 | |||
| 10/16/23 | Piper Sandler | Maintained Buy | $13 | |||
| 08/08/23 | Piper Sandler | Maintained Buy | $14 | |||
| 08/04/23 | Morgan Stanley | Maintained Hold | $13 |
Adaptive Biotechnologies Corporation Registered Shs Estimates* in USD
| 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|
| Revenue | 219 | 264 | 329 | 362 |
| Dividend | - | - | 0.00 | 0.00 |
| Dividend Yield (in %) | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| EPS | -0.84 | -0.65 | -0.38 | 0.07 |
| P/E Ratio | -10.94 | -14.17 | -24.05 | 130.57 |
| EBIT | - | - | -52 | 15 |
| EBITDA | -46 | 7 | 40 | 107 |
| Net Profit | - | - | -60 | 13 |
| Net Profit Adjusted | -121 | -71 | -36 | 13 |
| Pre-Tax Profit | - | - | -60 | 13 |
| Pre-Tax Profit Reported | -121 | -71 | -36 | - |
| EPS (Non-GAAP) ex. SOE | -0.81 | -0.47 | -0.21 | 0.07 |
| EPS (GAAP) | -0.86 | -0.63 | -0.21 | 0.07 |
| Gross Income | - | 171 | 239 | - |
| Cash Flow from Investing | -7 | -13 | -16 | -18 |
| Cash Flow from Operations | -52 | -26 | -7 | 47 |
| Cash Flow from Financing | 0 | - | - | 100 |
| Cash Flow per Share | -0.35 | -0.17 | -0.04 | - |
| Free Cash Flow | -21 | 13 | 37 | 97 |
| Free Cash Flow per Share | -0.39 | -0.26 | -0.14 | - |
| Book Value per Share | 0.71 | 0.31 | 0.48 | 1.05 |
| Net Debt | -15 | 25 | 8 | 34 |
| Research & Development Exp. | - | 95 | 110 | - |
| Capital Expenditure | 7 | 13 | 16 | 18 |
| Selling, General & Admin. Exp. | 162 | 153 | 150 | 142 |
| Shareholder’s Equity | 113 | 11 | 74 | 188 |
| Total Assets | 444 | 384 | 453 | 573 |
|
Previous Quarter ending 03/31/25 |
Current Quarter ending 06/30/25 |
Next Quarter ending 09/30/25 |
Current Year ending 12/31/25 |
Next Year ending 12/31/26 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 8 | 8 | 8 | 8 |
| Average Estimate | - | -0.237 USD | -0.207 USD | -0.836 USD | -0.645 USD |
| Year Ago | - | -0.314 USD | -0.217 USD | -1.084 USD | - |
| Publish Date | - | 7/30/2025 | 10/30/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 7 | 7 | 8 | 8 |
| Average Estimate | - | 50 USD | 56 USD | 219 USD | 264 USD |
| Year Ago | - | 43 USD | 46 USD | 179 USD | - |
| Publish Date | - | 7/30/2025 | 10/30/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales | 178.96 | 170.28 | 185.31 | 154.34 | 98.38 | 85.07 | 55.66 |
| Change of sales in % | 5.10 | -8.11 | 20.06 | 56.88 | 15.65 | 52.83 | 44.77 |
| Gross profit on sales | 96.55 | 72.49 | 106.48 | 91.09 | 67.38 | 56.03 | 32.18 |
| Gross profit on sales change in % | 33.19 | -31.92 | 16.89 | 35.19 | 20.25 | 74.14 | 69.57 |
| Operating income | -153.34 | -201.61 | -198.16 | -208.97 | -152.82 | -78.39 | -49.76 |
| Operating income change in % | 23.94 | -1.74 | 5.17 | -36.74 | -94.94 | -57.55 | -14.03 |
| Income before tax | -159.60 | -225.30 | -200.37 | -207.30 | -146.23 | -68.61 | -46.45 |
| Income before tax change in % | 29.16 | -12.45 | 3.34 | -41.76 | -113.14 | -47.71 | -8.44 |
| Income after tax | -159.49 | -225.25 | -200.19 | -207.28 | -146.23 | -69.57 | -46.35 |
| Income after tax change in % | 29.19 | -12.52 | 3.42 | -41.75 | -110.19 | -50.11 | -8.55 |
Balance Sheet in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 336.89 | 352.86 | 392.52 | 319.24 | 373.15 | 341.26 | 590.80 |
| Long-term liabilities per share | 1.62 | 1.83 | 1.98 | 1.45 | 1.95 | 2.10 | 4.61 |
| Equity | 202.49 | 308.28 | 464.10 | 604.10 | 743.27 | 571.04 | -258.11 |
| Equity change in % | -34.27 | -33.56 | -23.15 | -18.74 | 30.16 | - | -14.91 |
| Balance sheet total | 539.38 | 661.13 | 856.62 | 923.34 | 1,116.41 | 912.30 | 332.69 |
| Balance sheet total change in % | -18.42 | -22.82 | -7.23 | -17.29 | 22.37 | 174.22 | -8.22 |
Key Data in USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 1.22 | 1.18 | 1.30 | 1.10 | 0.75 | 1.23 | 0.45 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Equity ratio in % | 37.54 | 46.63 | 54.18 | 65.43 | 66.58 | 62.59 | -77.58 |
| Debt ratio in % | 62.46 | 53.37 | 45.82 | 34.57 | 33.42 | 37.41 | 177.58 |
Adaptive Biotechnologies Corporation Registered Shs Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| PISKEL KYLE | 05/15/2025 | 1,929.00 | 269,581.00 | 8.89 | Sell | No |
| ROBINS HARLAN S | 03/23/2025 | 1,698.00 | 1,279,524.00 | 9.00 | Sell | No |
| ROBINS HARLAN S | 03/23/2025 | 1,698.00 | 1,281,222.00 | 6.32 | Buy | No |
| PISKEL KYLE | 03/13/2025 | 2,500.00 | 271,510.00 | 6.32 | Buy | No |
| GRIFFIN MICHELLE RENEE | 03/12/2025 | 36,291.00 | 15,394.00 | 7.19 | Sell | No |
| HERSHBERG ROBERT | 03/11/2025 | 53,000.00 | 69,690.00 | 7.59 | Sell | No |
| NEUPERT PETER M | 03/09/2025 | 10,000.00 | 224,690.00 | 7.05 | Sell | No |
| NEUPERT PETER M | 03/09/2025 | 50,000.00 | 234,690.00 | 4.07 | Buy | No |
| ROBINS CHAD M | 03/05/2025 | 102,218.00 | 2,959,249.00 | 7.64 | Sell | No |
| GRIFFIN MICHELLE RENEE | 03/05/2025 | 15,664.00 | 51,685.00 | 7.94 | Sell | No |
| ROBINS CHAD M | 03/04/2025 | 36,145.00 | 2,814,350.00 | 6.99 | Sell | No |
| ROBINS CHAD M | 03/04/2025 | 81,206.00 | 2,850,495.00 | 6.98 | Sell | No |
| ROBINS HARLAN S | 03/04/2025 | 56,053.00 | 1,279,524.00 | 6.99 | Sell | No |
| ROBINS HARLAN S | 03/04/2025 | 40,603.00 | 1,335,577.00 | 6.98 | Sell | No |
| PISKEL KYLE | 03/04/2025 | 6,964.00 | 269,010.00 | 6.99 | Sell | No |
| PISKEL KYLE | 03/04/2025 | 253.00 | 275,974.00 | 6.98 | Sell | No |
| PISKEL KYLE | 03/04/2025 | 3,103.00 | 276,227.00 | 6.97 | Sell | No |
| RUBINSTEIN JULIE | 03/04/2025 | 19,461.00 | 588,249.00 | 6.99 | Sell | No |
| RUBINSTEIN JULIE | 03/04/2025 | 40,044.00 | 607,710.00 | 6.98 | Sell | No |
| LO FRANCIS | 03/04/2025 | 13,790.00 | 332,846.00 | 6.99 | Sell | No |
| LO FRANCIS | 03/04/2025 | 7,085.00 | 346,636.00 | 6.98 | Sell | No |
| BENZENO SHARON | 03/04/2025 | 3,065.00 | 392,723.00 | 6.99 | Sell | No |
| BENZENO SHARON | 03/04/2025 | 41,600.00 | 395,788.00 | 6.98 | Sell | No |
| BOBULSKY SUSAN | 03/04/2025 | 26,023.00 | 347,238.00 | 6.98 | Sell | No |
| ROBINS CHAD M | 03/04/2025 | 247,117.00 | 3,061,467.00 | n/a | Buy | No |
Adaptive Biotechnologies Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | Adaptive Biotechnologies Corporation Registered Shs | 0.00 | 0.00 | USD |
| 2023 | Adaptive Biotechnologies Corporation Registered Shs | 0.00 | 0.00 | USD |
| 2022 | Adaptive Biotechnologies Corporation Registered Shs | 0.00 | 0.00 | USD |
| 2021 | Adaptive Biotechnologies Corporation Registered Shs | 0.00 | 0.00 | USD |
| 2020 | Adaptive Biotechnologies Corporation Registered Shs | 0.00 | 0.00 | USD |
| 2019 | Adaptive Biotechnologies Corporation Registered Shs | 0.00 | 0.00 | USD |
| 2018 | Adaptive Biotechnologies Corporation Registered Shs | - | - | USD |
| 2017 | Adaptive Biotechnologies Corporation Registered Shs | - | - | USD |
*Yield of the Respective Date
Adaptive Biotechnologies Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Annual General Meeting | -1.080 USD | Annual General Meeting | 06/10/2025 |
| Earnings Report | -0.237 USD | Q2 2025 Earnings Release | 07/30/2025 |
| Earnings Report | -0.207 USD | Q3 2025 Earnings Release | 10/30/2025 |
| Earnings Report | -0.189 USD | Q4 2025 Earnings Release | 02/17/2026 |
| Earnings Report | -0.184 USD | Q1 2026 Earnings Release | 05/06/2026 |
Adaptive Biotechnologies Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | -0.200 USD | Q1 2025 Earnings Release | 05/01/2025 |
| Earnings Report | -0.230 USD | Q4 2024 Earnings Release | 02/11/2025 |
| Earnings Report | -0.220 USD | Q3 2024 Earnings Release | 11/07/2024 |
| Earnings Report | -0.310 USD | Q2 2024 Earnings Release | 08/01/2024 |
| Annual General Meeting | -1.560 USD | Annual General Meeting | 06/07/2024 |
| Earnings Report | -0.330 USD | Q1 2024 Earnings Release | 05/07/2024 |
| Earnings Report | -0.480 USD | Q4 2023 Earnings Release | 02/14/2024 |
| Earnings Report | -0.350 USD | Q3 2023 Earnings Release | 11/09/2023 |
| Earnings Report | -0.330 USD | Q2 2023 Earnings Release | 08/02/2023 |
| Annual General Meeting | -1.400 USD | Annual General Meeting | 06/09/2023 |
| Earnings Report | -0.400 USD | Q1 2023 Earnings Release | 05/03/2023 |
| Earnings Report | -0.280 USD | Q4 2022 Earnings Release | 02/14/2023 |
| Earnings Report | -0.320 USD | Q3 2022 Earnings Release | 11/03/2022 |
| Earnings Report | -0.370 USD | Q2 2022 Earnings Release | 08/03/2022 |
| Annual General Meeting | -1.480 USD | Annual General Meeting | 06/10/2022 |
| Earnings Report | -0.440 USD | Q1 2022 Earnings Release | 05/04/2022 |
| Earnings Report | -0.430 USD | Q4 2021 Earnings Release | 02/15/2022 |
Adaptive Biotechnologies Corporation Registered Shs Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.